| Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. | |
| | |
MedLine Citation:
|
PMID: 21044019 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Ezetimibe (EZE), a selective inhibitor of intestinal cholesterol absorption, is mostly used in combination with statins across various patient populations. Besides its low-density lipoprotein cholesterol (LDL-C) lowering, EZE exerts different effects on several other variables. In an earlier review, we discussed the effects of EZE on lipid parameters other than LDL-C [e.g. C-reactive protein (CRP) levels, insulin sensitivity and endothelial function]. In the present review, we consider recent evidence regarding these topics as well as data reporting novel EZE actions. EZE may protect from cholelithiasis and non-alcoholic fatty liver disease (NAFLD) and appears as an effective lipid-lowering treatment option for human-immunodeficiency virus (HIV)-positive patients, transplant recipients and children with familial hypercholesterolaemia (FH). Studies with EZE that raised concern about its effects on atherosclerosis are also discussed. The potential clinical benefit of these actions with respect to vascular events and overall mortality remains to be established in appropriately designed trials. |
| | |
Authors:
|
Eirini Lioudaki; Emmanuel S Ganotakis; Dimitri P Mikhailidis |
Related Documents
:
|
10193729 - Inhibition of thrombin generation by simvastatin and lack of additive effects of aspiri... 12441019 - Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. 9327779 - Efficacy and safety of a new hydroxymethylglutaryl-coenzyme a reductase inhibitor, ator... 15752919 - Management of diabetic dyslipidemia. 12624559 - The intestinal absorption of biliary and dietary cholesterol as a drug target for lower... 15248139 - Nitric oxide production in hiv-1 infected patients receiving intermittent cycles of int... 17999389 - Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. 18204929 - Growth of zinc-deficient rats during intra-gastric tube feeding. 21554339 - Potential application of the nisin z preparation of lactococcus lactis w8 in preservati... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current vascular pharmacology Volume: 9 ISSN: 1875-6212 ISO Abbreviation: Curr Vasc Pharmacol Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 62-86 Citation Subset: IM |
Affiliation:
|
Department of Clinical Biochemistry (Vascular Disease Prevention Clinic), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New concept of vascular calcification and metabolism.
Next Document: Vascular protective effects of ezetimibe: seeking new therapeutic possibilities of ezetimibe in vasc...